Cargando…

Angiotensin II Receptor Blockers and Arrhythmias in Ventricular Hypertrophy

Detalles Bibliográficos
Autor principal:	Salama, Guy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375503/ https://www.ncbi.nlm.nih.gov/pubmed/35862170 http://dx.doi.org/10.1161/JAHA.122.026634

Ejemplares similares

Angiotensin II receptor blockers and cardiovascular protection: Focus on left ventricular hypertrophy regression and atrial fibrillation prevention
por: Cuspidi, Cesare, et al.
Publicado: (2008)

Effects of the Angiotensin Receptor Blocker Olmesartan on Adipocyte Hypertrophy and Function in Mice with Metabolic Disorders
por: Maeda, Akinobu, et al.
Publicado: (2014)

Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
por: Holloway-Kew, Kara L., et al.
Publicado: (2022)

Inhibition of Angiotensin II-Induced Cardiac Hypertrophy and Associated Ventricular Arrhythmias by a p21 Activated Kinase 1 Bioactive Peptide
por: Wang, Rui, et al.
Publicado: (2014)

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19
por: Moore, Graham J., et al.
Publicado: (2021)

Prediction of left ventricular reverse remodeling after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and β blockers in patients with idiopathic dilated cardiomyopathy
por: Matsumura, Yoshihisa, et al.
Publicado: (2015)

The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Moretti, Myla E., et al.
Publicado: (2012)

Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
por: Zhang, Chao, et al.
Publicado: (2021)

Pneumonia Risk and Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Liu, Chia-Lin, et al.
Publicado: (2013)

Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
por: Lee, Hyun Woo, et al.
Publicado: (2021)

Clinical Pharmacogenetics of Angiotensin II Receptor Blockers in Iraq
por: Al-Hussaniy, Hany A., et al.
Publicado: (2023)

Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta‐blockers in patients hospitalized for acute heart failure
por: Carubelli, Valentina, et al.
Publicado: (2021)

Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID‐19
por: Pan, Michael, et al.
Publicado: (2021)

Differential Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on COVID-19
por: Su, Lianjiu, et al.
Publicado: (2021)

Visit-to-Visit Variability and Seasonal Variation in Blood Pressure With Single-Pill Fixed-Dose Combinations of Angiotensin II Receptor Blocker/Calcium Channel Blocker and Angiotensin II Receptor Blocker/Diuretic in Hypertensive Patients
por: Shiga, Yuhei, et al.
Publicado: (2015)

Summertime dosage-dependent hypersensitivity to an angiotensin II receptor blocker
por: Forsdyke, Donald R
Publicado: (2015)

Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker
por: Jun, Hye-Ran, et al.
Publicado: (2021)

Angiotensin II type 1 receptor blockers favorably affect renal angiotensin II and MAS receptor expression in patients with diabetic nephropathy
por: Ma, Ye-Ping, et al.
Publicado: (2020)

The impact of a dose of the angiotensin receptor blocker valsartan on post‐myocardial infarction ventricular remodelling
por: Park, Kyungil, et al.
Publicado: (2018)

Angiotensin Converting Enzyme Inhibitors versus Receptor Blockers in Patients with Ventricular Tachyarrhythmias
por: Schupp, Tobias, et al.
Publicado: (2022)

Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question
por: Lee, Hyun Woong
Publicado: (2014)

Is hypertensive left ventricular hypertrophy a cause of sustained ventricular arrhythmias in humans?
por: Nadarajah, R., et al.
Publicado: (2021)

Clinical Profile of Eprosartan: A Different Angiotensin II Receptor Blocker
por: Blankestijn, P. J, et al.
Publicado: (2008)

Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation
por: Naccarelli, Gerald V, et al.
Publicado: (2009)

Angiotensin receptor blockers in heart failure after the ELITE II trial
por: Willenheimer, Ronnie
Publicado: (2000)

Angiotensin II receptor blockers induce autophagy in prostate cancer cells
por: Woo, Yunseo, et al.
Publicado: (2017)

Circulating angiotensin II deteriorates left ventricular function with sympathoexcitation via brain angiotensin II receptor
por: Shinohara, Keisuke, et al.
Publicado: (2015)

Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: Anti-arrhythmic Drug for Arrhythmogenic Right Ventricular Cardiomyopathy
por: Tu, Bin, et al.
Publicado: (2021)

Additional antihypertensive effect of magnesium supplementation with an angiotensin II receptor blocker in hypomagnesemic rats
por: Jin, Kyubok, et al.
Publicado: (2013)

Influence of angiotensin II receptor blocker combination tablet prescription on drug number and cost
por: Teramachi, Hitomi, et al.
Publicado: (2014)

Evaluation of angiotensin II receptor blockers for drug formulary using objective scoring analytical tool
por: Lim, Tsuey M., et al.
Publicado: (2012)

Olmesartan Medoxomil, An Angiotensin II-Receptor Blocker, Ameliorates Renal Injury In db/db Mice
por: Zhu, Ye, et al.
Publicado: (2019)

Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD
por: Lai, Chih-Cheng, et al.
Publicado: (2018)

Sex Differences in the Effectiveness of Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Sacubitril–Valsartan for the Treatment of Heart Failure
por: Sohani, Zahra N., et al.
Publicado: (2023)

Angiotensin receptor blockers and COVID-19
por: Saavedra, Juan M.
Publicado: (2020)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic
por: Volpe, Massimo, et al.
Publicado: (2012)

Arrhythmia related to hypertensive left ventricular hypertrophy in Iraqi patients: frequency and outcome
por: Al Alwany, Ameen Abdulhasan
Publicado: (2022)

Left ventricular hypertrophy and renin-angiotensin system blockade
por: Cowan, Brett R., et al.
Publicado: (2009)

Effects of the beta-blocker carvedilol on arrhythmia and long-term clinical outcomes in benign prostate hypertrophy patients
por: Kim, Soo Jin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_72b76fgf5uia8hbeid4kd3jkcq